Bio-Techne (NASDAQ: TECH) grants CFO 22,438 and 36,459 RSUs
Bio-Techne (NASDAQ: TECH) CFO James Hippel was granted two equity awards on August 17, 2026, consisting of 22,438 and 36,459 Restricted Stock Units (RSUs). These RSUs represent a contingent right to one share of common stock each, with specific vesting schedules extending through August 2029. The filing also details Hippel's existing holdings, including stock options and 170,183 directly owned common shares.
Bio-Techne (TECH) director granted 1,381 RSUs vesting 2027-29
Bio-Techne director Amy E. Herr was granted 1,381 indirect Restricted Stock Units (RSUs) on August 17, 2026, through a significant other, which will vest in three annual installments from 2027 to 2029. This Form 4 filing also details her existing stock options with various exercise prices and expiration dates, and current direct and indirect common stock holdings. No sales or option exercises were reported in this filing.
Bio-Techne (TECH) insider updates stock holdings
William Geist, President of Protein Sciences at Bio-Techne Corp (TECH), has reported 13 insider transactions involving grants of restricted stock units. The Form 4 filing details direct holdings including 44,596 Restricted Stock Units, 123,059 Stock Options (Right to Buy), 35,093 Performance Restricted Stock Units, and 24,943 Common Stock shares after these transactions. The filing indicates a neutral impact and sentiment regarding these stock holding updates.
Bio-Techne (NASDAQ: TECH) grants president 8,702 and 14,140 RSUs
Bio-Techne (NASDAQ: TECH) President Steven C. Crouse was granted two equity awards on August 17, 2026, consisting of 8,702 and 14,140 restricted stock units (RSUs), with multi-year vesting schedules extending through 2029. Following these grants, Crouse directly holds 10,237 shares of common stock and various stock options. The filing details his current holdings and the vesting terms of these and other equity awards.
Benchmark reiterates Hold stock rating on Bio-Techne after Q4 results
Benchmark has reiterated a Hold rating on Bio-Techne Corp. following its Q4 fiscal 2026 results. The company reported revenues of $321.2 million, a 1% year-over-year increase, and non-GAAP earnings of $0.52 per share. Bio-Techne is expected to be acquired by Merck KGaA later this year or early next year.
Benchmark reiterates Hold stock rating on Bio-Techne after Q4 results
Benchmark has reiterated its Hold rating on Bio-Techne Corp. (NASDAQ:TECH) following the company's Q4 fiscal 2026 results. Bio-Techne reported revenues of $321.2 million, a 1% year-over-year increase, with non-GAAP earnings of $0.52 per share. The company is currently trading near its 52-week high and is expected to be acquired by Merck KGaA later this year or early next year.
Benchmark reiterates Hold stock rating on Bio-Techne after Q4 results
Benchmark has reiterated a Hold rating on Bio-Techne Corp. following its fourth-quarter fiscal 2026 results. The company reported revenues of $321.2 million, a 1% year-over-year increase, and non-GAAP earnings of $0.52 per share. Bio-Techne is also on track to be acquired by Merck KGaA later this year or early next.
Benchmark reiterates Hold stock rating on Bio-Techne after Q4 results
Benchmark has reiterated its Hold rating on Bio-Techne Corp. (NASDAQ:TECH) following the company's Q4 fiscal 2026 results. Bio-Techne reported revenues of $321.2 million, a 1% year-over-year increase, and non-GAAP earnings of $0.52 per share. The company is currently in the process of being acquired by Merck KGaA.
Benchmark reiterates Hold stock rating on Bio-Techne after Q4 results
Benchmark has reiterated its Hold rating on Bio-Techne Corp. (NASDAQ:TECH) following the company's Q4 fiscal 2026 results. Bio-Techne reported a 1% year-over-year revenue increase to $321.2 million and adjusted earnings of $0.52 per share. The company, trading near its 52-week high, is slated for acquisition by Merck KGaA later this year or early next.
BIO-TECHNE Executive Steven C. Crouse Files Form 4 After RSU Vesting and Share Withholding
Steven C. Crouse, President of Diagnostics and Spatial Biology at BIO-TECHNE Corp (NASDAQ:TECH), filed a Form 4 detailing stock transactions on August 18, 2026. The filing reported the vesting of 5,423 restricted stock units (RSUs) and the withholding of 1,947 shares at $72.4 per share to cover tax obligations. After these transactions, Crouse directly owns 10,237 shares of BIO-TECHNE common stock, with additional derivative holdings and unvested RSUs.
Bio-Techne (TECH) CEO exercises awards, 10.8K shares withheld
Bio-Techne CEO Kim Kelderman reported multiple equity award updates on August 15, 2026, acquiring 21,470 shares of common stock through exercises while 10,821 shares were withheld for tax and exercise costs. The Board authorized discretionary vesting for certain performance restricted stock units and options, with the remaining portions forfeited. Kelderman continues to hold substantial stock options and performance RSUs.
Bio-Techne (TECH) CFO exercises awards, covers taxes in stock
Bio-Techne (TECH) CFO James Hippel reported equity-award transactions on August 15, 2026, acquiring 9,779 common shares through restricted stock unit exercises and having 4,310 shares withheld at $72.40 for tax liabilities. The board also authorized discretionary vesting for 866 performance RSUs and 2,332 performance options, with remaining awards forfeited. Hippel continues to hold various option and RSU awards expiring through 2035.
Bio-Techne (TECH) awards give executive 5,423 shares, 1,947 withheld
Bio-Techne (TECH) executive Steven C. Crouse, President - Diag & Spatial Bi, converted 5,423 restricted stock units into common stock on August 15, 2026. In connection with this, 1,947 shares were withheld at $72.40 per share to cover exercise price or tax liabilities. Crouse continues to hold a substantial number of equity awards, including various stock options and restricted stock units with vesting dates extending into 2036.
Bio-Techne (TECH) director exercises 589 RSUs, uses shares for taxes
Bio-Techne (TECH) director Amy E. Herr reported the exercise of 589 restricted stock units (RSUs) indirectly through her significant other on August 15, 2026. A portion of these shares, 213 common shares, were subsequently used to cover tax liabilities at a price of $72.40 per share. Following these transactions, Herr directly holds 2,680 shares of BIO-TECHNE common stock and maintains various indirect stock option and RSU positions.
S&CO Inc. Buys Shares of 76,614 Bio-Techne Corp $TECH
S&CO Inc. has acquired a new stake of 76,614 shares in Bio-Techne Corp (NASDAQ:TECH), valued at approximately $5.41 million. Other institutional investors have also adjusted their positions in the biotechnology company, with institutional investors and hedge funds collectively owning 98.95% of its stock. Bio-Techne recently reported quarterly earnings, increased its dividend, and received several analyst rating changes, with an average "Hold" rating from analysts.
Mdxhealth Reports Second Quarter 2026 Financial Results
Mdxhealth reported a 16% increase in second-quarter 2026 revenue, reaching $27.2 million, driven by strong recovery in its tissue-based business and integration of ExoDx. The company reaffirmed its 2026 revenue guidance of $110-115 million and expects to return to positive adjusted EBITDA by the end of 2026. This growth follows the strategic discontinuation of its Resolve UTI offering and a recent registered direct placement of shares, strengthening its financial position.
TECH Q4 Earnings Meet Estimates, Revenues Surpass, Stock Rises
Bio-Techne Corporation (TECH) reported Q4 fiscal 2026 adjusted earnings per share that met estimates and revenues that surpassed them, leading to a slight increase in stock price. The company's net sales grew by 1% year-over-year, with strong organic growth in its Diagnostics and Spatial Biology segments. Bio-Techne is set to be acquired by Merck KGaA for $11.3 billion, and this transaction remains a key focus.
TECH Q4 Earnings Meet Estimates, Revenues Surpass, Stock Rises
Bio-Techne Corporation (TECH) reported Q4 fiscal 2026 adjusted earnings per share of 52 cents, meeting analyst estimates, while revenues of $321.2 million surpassed expectations. Despite some segment-specific challenges and a contraction in adjusted gross margin, the company's shares rose following the announcement. The article also highlights Bio-Techne's pending acquisition by Merck KGaA for $73 per share, representing an enterprise value of approximately $11.3 billion.
TECH Q4 Earnings Meet Estimates, Revenues Surpass, Stock Rises
Bio-Techne Corporation (TECH) reported Q4 fiscal 2026 adjusted earnings per share of 52 cents, meeting Zacks Consensus Estimates, while net sales of $321.2 million surpassed expectations. Despite some mixed segment performances and a contraction in adjusted gross margin, the company's shares rose slightly. The article also highlights Bio-Techne's agreement to be acquired by Merck KGaA for approximately $11.3 billion, which is progressing.
Bio-Techne Keeps Quarterly Dividend at $0.08 a Share, Payable Aug. 28 to Shareholders of Record as of Aug. 24
Bio-Techne Corporation announced it will maintain its quarterly dividend at $0.08 per share. This dividend is payable on August 28, 2026, to shareholders of record as of August 24, 2026. The announcement was made on August 12 and reiterates the company's consistent dividend policy.
Bio-Techne Corp (NASDAQ:TECH) to Issue Dividend Increase - $0.65 Per Share
Bio-Techne Corp (NASDAQ:TECH) announced a significant increase in its quarterly dividend to $0.65 per share, up 712.5% from its previous dividend of $0.08. Investors of record by September 4th will receive this dividend on September 24th, resulting in a 3.6% dividend yield. The company's payout ratio remains low at 15.4%, indicating strong dividend coverage by earnings.
Bio-Techne corrects dividend record date to August 24, 2026, with $0.08 per share payout on August 28.
Bio-Techne Corporation has corrected the record date for its quarterly dividend to August 24, 2026, from the previously announced August 17, 2026. Shareholders recorded on this new date will receive a dividend of $0.08 per share on August 28, 2026. This adjustment aligns with the company's established quarterly dividend policy.
Bio-Techne Releases Fourth Quarter Fiscal 2026 Results
Bio-Techne Corporation has released its financial results for the fourth quarter and full fiscal year ending June 30, 2026. The company reported a 3% organic revenue increase for Q4 FY26, reaching $321.2 million, and announced its agreement to be acquired by Merck KGaA for approximately $11.3 billion. Bio-Techne will no longer hold investor conference calls due to the pending acquisition.
Merck's planned $11.3B acquisition of Bio-Techne moves forward
Bio-Techne reported Q4 FY2026 net sales of $321.2 million, a 1% increase (3% organically), with GAAP EPS of $0.35 and adjusted EPS of $0.52. The full fiscal year 2026 saw flat revenue at $1.2 billion, but GAAP EPS increased to $1.16 and adjusted EPS to $1.93. The company also confirmed progress towards its acquisition by Merck KGaA for $73 per share in cash, valuing the transaction at approximately $11.3 billion, leading to the cessation of quarterly investor calls.
Bio-Techne declares $0.08 quarterly dividend
Bio-Techne Corporation (NASDAQ:TECH) has declared a quarterly dividend of $0.08 per share for the quarter ending June 30, 2026. This dividend is payable on August 28, 2026, to shareholders of record as of August 17, 2026. The Minnesota-based life sciences company, which generated over $1.2 billion in net sales in fiscal year 2026, plans for its Board of Directors to consider future cash dividends on a quarterly basis.
Form 8K Bio-Techne Corp For: 12 August By Investing.com
This article announces that Bio-Techne Corp filed a Form 8K on August 12, as reported by Investing.com. The content is a brief notification without further details on the filing's specifics. The article also lists various market data, including indices, commodities, and shares, as well as trending news and stock performance.
Bio-Techne Corp to Issue Quarterly Dividend of $0.08 (NASDAQ:TECH)
Bio-Techne Corp (NASDAQ:TECH) has declared a quarterly dividend of $0.08 per share, payable on August 28th to shareholders of record as of August 17th, equating to an annualized dividend of $0.32 and a 0.4% yield. The dividend is well-covered by earnings, with a payout ratio of 15.4%. The company recently reported quarterly EPS of $0.52, meeting analyst estimates, and revenue of $321.19 million, exceeding expectations, while analysts maintain a consensus "Hold" rating with an average price target of $68.08.
Activist investor gets aggressive with offer to buy H.B. Fuller unit for more than $1B
Activist investor Ancora Holdings Group has publicly offered to buy H.B. Fuller's building adhesive solutions unit for $1.1 billion to $1.2 billion. This aggressive move comes after private discussions and expresses Ancora's frustration with H.B. Fuller's acquisition strategy, particularly its recent $943 million offer to buy Advanced Medical Solutions Group. Ancora, which owns 2% of Fuller's stock, believes the sale would benefit Fuller by helping it meet deleveraging goals and focus on other acquisitions.
Better Healthcare ETF: State Street's Pharmaceuticals-Focused XPH vs. Invesco's S&P 500-Targeted RSPH
This article compares two healthcare-focused ETFs: State Street's SPDR S&P Pharmaceuticals ETF (XPH) and Invesco's S&P 500 Equal Weight Health Care ETF (RSPH). XPH focuses specifically on the pharmaceutical industry and has shown stronger recent performance, while RSPH offers broader, equal-weighted exposure to the entire S&P 500 healthcare sector. The choice between them depends on an investor's preference for focused pharmaceutical exposure versus diversified healthcare coverage, considering factors like expense ratios, volatility, and historical returns.
Bio-Techne declares $0.08 quarterly dividend payable August 28, 2026.
Bio-Techne Corporation announced a quarterly dividend of $0.08 per share for the quarter ending June 30, 2026, payable on August 28, 2026, to shareholders of record as of August 17, 2026. The global life sciences firm, with over $1.2 billion in net sales for fiscal 2026, plans to review future dividends quarterly as part of its commitment to shareholder value. This dividend declaration follows their recent financial report showing flat FY2026 revenue but an increase in EPS, alongside confirming an $11.3 billion acquisition by Merck KGaA.
Bio-Techne beats revenue estimates on research, diagnostics demand uptick
Bio-Techne surpassed Wall Street's revenue expectations for the fourth quarter, driven by strong growth in its research and diagnostics segments. The company's Protein Sciences segment saw a 2.1% increase in revenue, while its Diagnostics and Spatial Biology segment grew by 0.5%. Bio-Techne is currently in the process of being acquired by Merck KGaA for approximately $11.3 billion.
Bio-Techne reports in-line Q4 earnings, beats on revenue
Bio-Techne Corporation reported fourth-quarter fiscal 2026 results that met analyst expectations for earnings with an adjusted EPS of $0.52, while exceeding revenue estimates at $321.2 million. Revenue increased 1% reported and 3% organically year-over-year. The company is awaiting the completion of its acquisition by Merck KGaA for $73 per share in cash.
Bio-Techne Q4 Adjusted Earnings Fall, Revenue Rise
Bio-Techne Corporation reported a fall in adjusted earnings for its fourth quarter, though revenue increased to $321.2 million, surpassing FactSet estimates of $314.6 million. The company posted an adjusted EPS of $0.52 per share, matching FactSet's estimate. Bio-Techne specializes in manufacturing and marketing products for life science research, with net sales primarily from biological and chemical reagents and analysis tools.
Earnings Flash (TECH) Bio-Techne Corporation Reports Q4 Revenue $321.2M, vs. FactSet Est of $314.6M
Bio-Techne Corporation (TECH) announced its Q4 revenue of $321.2 million, surpassing FactSet's estimate of $314.6 million. The company's adjusted EPS for Q4 was $0.52 per share, matching FactSet's estimate. This positive revenue performance highlights strong demand in its research and diagnostics segments.
Form 8K Bio-Techne Corp For: 12 August By Investing.com
This article announces the filing of a Form 8K by Bio-Techne Corp on August 12. The content itself is very brief, serving primarily as a notification for investors and links to related market data and news provided by Investing.com.
Bio-Techne Q4 Revenue Rises to $321.2 Million
Bio-Techne (TECH) reported a 1% increase in fiscal fourth-quarter net sales to $321.2 million, with organic revenue up 3%. The company also announced an agreement to be acquired by Merck KGaA for approximately $11.3 billion, leading to the cessation of investor conference calls. Insider trading data showed one sale by an insider and significant institutional investor activity, while members of Congress also reported sales of TECH stock.
Bio-Techne Sets Aug. 28 Payment Date for Dividend
Bio-Techne (NASDAQ: TECH) has declared a quarterly cash dividend of $0.08 per share for the quarter ended June 30, 2026. The dividend is payable on August 28, 2026, to shareholders of record as of August 17, 2026. The company also reported over $1.2 billion in net sales for fiscal year 2026 and operates globally with approximately 3,000 employees.
Gilead refreshes ADC biomarker collab with Nucleai
Gilead Sciences has renewed its collaboration with Israel-based Nucleai to apply Nucleai's AI-powered Tissue Intelligence platform for spatial biomarker generation and translational insights in Gilead's antibody-drug conjugate (ADC) clinical development programs. Nucleai's platform analyzes large datasets of H&E and IHC images, integrating computational pathology, spatial biology, and clinical outcomes to identify quantitative tissue features linked to patient response. This extended partnership underscores Nucleai's growing role in pharma-facing platform engagements within the ADC space and provides Gilead with advanced AI-driven biomarker analysis for its expanding ADC pipeline.
Bio-Techne Declares Dividend
Bio-Techne Corporation announced its Board of Directors has declared a quarterly dividend of $0.08 per share for the quarter ended June 30, 2026. The dividend is payable on August 28, 2026, to shareholders of record on August 17, 2026. Future dividends will be considered on a quarterly basis.
Bio-Techne (NASDAQ:TECH) Reaches New 12-Month High - Should You Buy?
Bio-Techne (NASDAQ:TECH) recently hit a new 52-week high of $72.37, though it was trading slightly below this at $72.25. Despite the high stock price, analyst sentiment remains cautious, with an average "Hold" rating and a target price of $68.08. The company has strong liquidity and low leverage but trades at a high valuation with a P/E ratio above 104.
Bio-Techne faces quarterly earnings test with Merck deal pending
Bio-Techne is set to report fiscal fourth-quarter earnings, but the focus remains on its pending acquisition by Merck KGaA for $11.3 billion. Analysts have largely downgraded the stock to Hold, with the stock price trading near the offer price, indicating that quarterly results are less significant than the deal's execution. Investors will be scrutinizing management commentary on deal closure, operational momentum, and core business stabilization.
Bio-Techne Corp (TECH) Stock Analysis & Forecast
Germany's Merck Group announced on June 25 that it will acquire the US life sciences company Bio-Techne (TECH) for $73 per share in an all-cash transaction. This acquisition represents an enterprise value of approximately $11.3 billion and caused Bio-Techne's stock to jump over 20% premarket. The article provides an analysis review of Bio-Techne Corp stock, covering its valuation, outlook, chart signals, and key risks.
Bio-Techne Corp (TECH) Stock News Today
This page provides the latest news and analysis for Bio-Techne Corp (TECH) stock, including earnings reports and analyst ratings. It also features recent news articles concerning other pharmaceutical companies like AstraZeneca PLC, Merck & Co Inc, and AbbVie Inc, detailing their stock movements. The page serves as a hub for investors to track developments related to Bio-Techne and the broader biotechnology and medical research sector.
Merck lifts 2026 outlook as profits surge &Bio-Techne deal strengthens growth push
Merck has raised its full-year guidance for 2026 after reporting stronger-than-expected second-quarter results, driven by growth in life science, rare diseases, and semiconductor solutions. The company's proposed acquisition of Bio-Techne Corporation is expected to further bolster its leadership in high-growth life science markets. Merck saw significant organic growth across all key segments and regions, supported by increased demand and strategic investments.
Amundi Sells 148,342 Shares of Bio-Techne Corp $TECH
Amundi reduced its stake in Bio-Techne Corp (NASDAQ:TECH) by 67.2% during the first quarter, selling 148,342 shares and retaining 72,315 shares valued at approximately $3.8 million. Despite this, institutional ownership remains high at 98.95%, with other funds like Goldman Sachs and First Trust Advisors increasing their positions. The stock currently holds a consensus "Hold" rating from analysts with a target price of $68.08, and it recently traded near its 52-week high despite missing quarterly earnings and revenue estimates.
The Manufacturers Life Insurance Company Sells 39,950 Shares of Bio-Techne Corp $TECH
The Manufacturers Life Insurance Company reduced its stake in Bio-Techne Corp (NASDAQ:TECH) by 26.1% in the first quarter, selling 39,950 shares and retaining 113,374 shares valued at $5.9 million. Bio-Techne reported Q1 EPS of $0.53, missing analyst consensus of $0.55, with revenue down 1.5% year-over-year to $311.42 million. Despite the stock opening at $72.00, near its 52-week high, analysts hold a "Hold" consensus rating with an average price target of $68.08, following recent downgrades.
Investors’ Confidence in Bio-Techne Corp. (TECH) Strengthens as Headwind Eases
Conestoga Capital Advisors highlighted Bio-Techne Corporation (TECH) as a performance contributor in its Q2 2026 investor letter. The company, a leader in life science research, is benefiting from subsiding temporary headwinds, including improving academic funding and strong large pharmaceutical customer demand. Bio-Techne recently agreed to an acquisition by Merck KGaA, and its shares have seen significant gains over the past year.
Research Use (RUO) Recombinant Protein Market
The Research Use (RUO) Recombinant Protein Market is projected to grow from USD 1.11 billion in 2026 to USD 1.55 billion by 2031, at a CAGR of 7.0%. This growth is driven by expanding drug discovery, preclinical research, and the increasing use of advanced cell-based models. North America currently holds the largest market share, while Asia Pacific is expected to be the fastest-growing region.
Bio-Techne Number of Employees 2026 | Employee Count & Headcount Data
Bio-Techne Corp. (NASDAQ: TECH) had approximately 3,083 employees worldwide as of March 2026, marking a 0.3% increase since 2023. The company is actively hiring, with 268 job postings in 2026, a 10.6% increase from the previous year. While the workforce is concentrated in the United States, Germany is its fastest-growing location, and employee sentiment is reported as negative and declining.
Form 4 Bio-Techne Corp For: 31 July By Investing.com
This article reports on the filing of Form 4 by Bio-Techne Corp for July 31. The brief piece indicates that the filing is accessible via Investing.com and includes a stock ticker (TECH) along with a minor percentage change. The core content is primarily a record of a financial disclosure.
